Project Grant R01HL171482
Award Date
9/15/24
Completion Date
6/30/29
Dollars Obligated
$786K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Philadelphia, PA 19104, USA
Similar Awards
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $306,530 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Spinhance LLC, a for-profit limited liability company located in Rydal, Pennsylvania. The grant aims to design, build, and evaluate a novel cardiopulmonary imaging device for continuous administration of the magnetic resonance imaging (MRI) contrast agent hyperpolarized xenon-129. This system is intended to support a new paradigm for...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research Program (CFDA 93.837) aims to develop next-generation laser technology to enable more efficient and cost-effective production of hyperpolarized xenon-129 gas for functional pulmonary MRI imaging. The total funding amount is $231,207, awarded on September 1, 2024 to Wayne State University (WSU) to conduct this research. A sub-award of $XX,XXX was provided to...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $1,564,220 Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) to The Trustees of the University of Pennsylvania, doing business as Clinical Practices of the University of Pennsylvania, on Sep 17, 2024. The grant funds the development of an imaging-compatible pre-clinical ex vivo lung perfusion (EVLP) system to obtain structural, functional, and metabolic biomarkers of donor lung health. The project aims to use these...
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $191,913 to The University of Texas MD Anderson Cancer Center to research the use of hyperpolarized xenon-129 MRI as a predictive biomarker for mitigating radiation-induced lung injury (RILI) in lung cancer patients undergoing radiotherapy. The 5-year project aims to: 1) determine the effect of baseline lung function, tumor location, and radiation modality on...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research (CFDA 93.837) program, provides $742,810 to the University of Virginia to develop hyperpolarized gas MRI (HGMRI) signatures for detecting and monitoring acute cellular rejection in lung transplant recipients. The 5-year project aims to correlate HGMRI signatures with tissue pathology, treatment response, and single-cell RNA-sequencing data to enhance early...
This $604,115 federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) will support a longitudinal observational study by The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to develop non-invasive advanced imaging technologies to predict the development of progressive pulmonary fibrosis in individuals with non-idiopathic pulmonary fibrosis interstitial lung...
This is a Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), under the Cardiovascular Diseases Research (CFDA 93.837) program. The $827,682 award will fund a comprehensive research project to develop advanced imaging techniques, including dynamic contrast-enhanced CT, dual-energy CT, and electrical impedance tomography, to characterize pulmonary perfusion and guide personalized treatment of acute respiratory distress...
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $268,500 to Brigham & Women's Hospital Inc. to develop and validate a quantitative marker of pulmonary microvascular injury, and explore the correlation between microvascular volume loss and the progression of COPD and emphysema in smokers. The research aims to create an image-based quantifiable feature of pulmonary vascular injury, which will facilitate new...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $260,586 to the University of Wisconsin-Madison over a 5-year period starting September 1, 2024. The objective is to develop and optimize a novel positron emission tomography (PET) probe that can monitor extracellular matrix deposition and disease activity in idiopathic pulmonary fibrosis (IPF), a fatal lung disease characterized by...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $122,788 Project Grant under the Cardiovascular Diseases Research (CFDA 93.837) program to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), with a project period from September 15, 2024 to June 30, 2026. The goal of this project is to establish a pharmacokinetic model for absolute quantification of pulmonary perfusion and microvascular parameters, and validate this model in large animal...